Session » Epidemiology and Public Health Poster I

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0707

Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0700

Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning

9:00AM-10:30AM: Abstract Number: 0697

Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?

9:00AM-10:30AM: Abstract Number: 0706

Association Between Metabolic Syndrome and Knee Pain over 10-13 Years in Middle-Aged Adults

9:00AM-10:30AM: Abstract Number: 0718

Biomarkers Predict Worsening of Lumbar Spine Degeneration and Low Back Pain: The Johnston County Osteoarthritis Project

9:00AM-10:30AM: Abstract Number: 0722

Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry

9:00AM-10:30AM: Abstract Number: 0704

Clinically Suspect Arthralgia Patients with a Low Educational Attainment Have an Increased Risk to Develop Inflammatory Arthritis

9:00AM-10:30AM: Abstract Number: 0698

Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women

9:00AM-10:30AM: Abstract Number: 0712

Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study

9:00AM-10:30AM: Abstract Number: 0719

Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

9:00AM-10:30AM: Abstract Number: 0699

Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-10:30AM: Abstract Number: 0695

Epidemiology of Behçet’s Disease in Northern Spain

9:00AM-10:30AM: Abstract Number: 0702

Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study

9:00AM-10:30AM: Abstract Number: 0711

Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study

9:00AM-10:30AM: Abstract Number: 0721

Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex

9:00AM-10:30AM: Abstract Number: 0709

Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program

9:00AM-10:30AM: Abstract Number: 0716

Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic

9:00AM-10:30AM: Abstract Number: 0714

Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0701

Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period

9:00AM-10:30AM: Abstract Number: 0710

Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study

9:00AM-10:30AM: Abstract Number: 0723

Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study

9:00AM-10:30AM: Abstract Number: 0720

Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study

9:00AM-10:30AM: Abstract Number: 0715

Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort

9:00AM-10:30AM: Abstract Number: 0705

Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study

9:00AM-10:30AM: Abstract Number: 0713

The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States

9:00AM-10:30AM: Abstract Number: 0708

The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study

9:00AM-10:30AM: Abstract Number: 0696

The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database

9:00AM-10:30AM: Abstract Number: 0717

Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States

9:00AM-10:30AM: Abstract Number: 0703

Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].